IGM Biosciences Q2 EPS $(1.43), Inline, Sales $448.00K Miss $800.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
IGM Biosciences reported Q2 losses of $(1.43) per share, meeting analyst consensus. This is a 7.52% decrease from the same period last year. The company's quarterly sales of $448.00K missed the analyst consensus estimate of $800.00K by 44.00%, but it's a 22.40% increase from last year.
August 04, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IGM Biosciences' Q2 earnings met expectations but sales missed estimates by 44.00%. This could potentially impact the company's stock negatively in the short term.
IGM Biosciences' Q2 earnings were in line with analyst expectations, which is generally a positive signal. However, the company's sales missed estimates by a significant margin, which could lead to a negative market reaction and potentially drive the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100